CNB Bank’s Sarepta Therapeutics SRPT Stock Holding History

CNB Bank’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4	Closed	-$1K	–	428
2020 Q4	$1K	Buy	+4	New	+$593	﹤0.01%	420

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CNB Bank's SRPT Position: Q1 2021 in Review

CNB Bank sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 4 shares — an estimated $1K sold.

CNB Bank first reported a position in SRPT in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

CNB Bank reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
CNB Bank sold 4 Sarepta Therapeutics shares in Q1 2021, an estimated $1K.
CNB Bank first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 1 quarter.
CNB Bank's Sarepta Therapeutics position peaked at $1K in Q4 2020.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on CNB Bank's 13F filing for Q1 2021, filed 3 May 2021.